IL281339A - Antigen-specific t lymphocytes and methods of making and using the same - Google Patents

Antigen-specific t lymphocytes and methods of making and using the same

Info

Publication number
IL281339A
IL281339A IL281339A IL28133921A IL281339A IL 281339 A IL281339 A IL 281339A IL 281339 A IL281339 A IL 281339A IL 28133921 A IL28133921 A IL 28133921A IL 281339 A IL281339 A IL 281339A
Authority
IL
Israel
Prior art keywords
lymphocytes
antigen
preparation
methods
specific
Prior art date
Application number
IL281339A
Other languages
English (en)
Hebrew (he)
Original Assignee
Torque Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torque Therapeutics Inc filed Critical Torque Therapeutics Inc
Publication of IL281339A publication Critical patent/IL281339A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0006—Modification of the membrane of cells, e.g. cell decoration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/427—PRAME
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C12N5/064—Immunosuppressive dendritic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1114—T cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
IL281339A 2018-09-10 2021-03-09 Antigen-specific t lymphocytes and methods of making and using the same IL281339A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862729220P 2018-09-10 2018-09-10
US201962884527P 2019-08-08 2019-08-08
PCT/US2019/050492 WO2020055931A1 (en) 2018-09-10 2019-09-10 Antigen-specific t lymphocytes and methods of making and using the same

Publications (1)

Publication Number Publication Date
IL281339A true IL281339A (en) 2021-04-29

Family

ID=69778456

Family Applications (1)

Application Number Title Priority Date Filing Date
IL281339A IL281339A (en) 2018-09-10 2021-03-09 Antigen-specific t lymphocytes and methods of making and using the same

Country Status (7)

Country Link
US (1) US20220033766A1 (cg-RX-API-DMAC7.html)
EP (1) EP3849569A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022500034A (cg-RX-API-DMAC7.html)
AU (1) AU2019339332A1 (cg-RX-API-DMAC7.html)
CA (1) CA3112471A1 (cg-RX-API-DMAC7.html)
IL (1) IL281339A (cg-RX-API-DMAC7.html)
WO (1) WO2020055931A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230190902A1 (en) * 2020-05-29 2023-06-22 Children's National Medical Center Identification of hla-restricted prame peptide epitopes, prame-specific t cells suitable for "off-the-shelf" treatment of cancer expressing prame
WO2024026452A1 (en) 2022-07-29 2024-02-01 Repertoire Immune Medicines, Inc. T cell epitopes associated with type 1 diabetes
US20260234258A1 (en) 2022-10-20 2026-08-13 Repertoire Immune Medicines, Inc. Cd8 t cell targeted il2
WO2025072849A1 (en) 2023-09-29 2025-04-03 Repertoire Immune Medicines, Inc. Mhc-presentable peptides associated with type 1 diabetes

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE038833T2 (hu) * 2005-08-05 2018-11-28 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh Antigénspecifikus T-sejtek létrehozása
ES2635335T3 (es) * 2010-09-20 2017-10-03 Biontech Cell & Gene Therapies Gmbh Receptores de células T específicos de antígeno y epítopos de células T
US20140081012A1 (en) 2011-02-15 2014-03-20 The University Of North Carolina At Chapel Hill Nanoparticle, liposomes, polymers, agents and proteins modified with reversible linkers
CA3191031A1 (en) 2013-09-27 2015-04-02 Massachusetts Institute Of Technology Carrier-free biologically-active protein nanostructures
MX2017000630A (es) * 2014-07-15 2017-04-27 Immune Design Corp Regimenes de sensibilización-refuerzo con un adyuvante de agonista tlr4 y un vector lentiviral.
AU2016305087B2 (en) 2015-08-12 2022-01-20 Massachusetts Institute Of Technology Cell surface coupling of nanoparticles

Also Published As

Publication number Publication date
US20220033766A1 (en) 2022-02-03
JP2022500034A (ja) 2022-01-04
CA3112471A1 (en) 2020-03-19
EP3849569A4 (en) 2022-06-08
WO2020055931A1 (en) 2020-03-19
EP3849569A1 (en) 2021-07-21
AU2019339332A1 (en) 2021-04-08

Similar Documents

Publication Publication Date Title
IL282225A (en) Compositions and methods for immunotherapy
IL262095A (en) Anti-pacap antibodies and uses thereof
DK3293202T3 (da) Anti human interleukin-1 receptor accessory protein (il1rap) antibodies and uses thereof
IL280317A (en) Anti-avb8 antibodies and compositions and uses thereof
IL261713B1 (en) Methods and compositions for transducing lymphocytes and regulated expansion thereof
EP3740224A4 (en) ANTI-LILRB ANTIBODIES AND THEIR USES
ZA202104518B (en) Cd3 antibody and pharmaceutical use thereof
IL260151A (en) T cell receptors specific for the ny-eso-1 tumor antigen-hla-a 02 complex
PL3618928T3 (pl) Przeciwciała antysortylinowe i sposoby ich stosowania
PL3436079T3 (pl) Antygen chimeryczny i receptory komórek t oraz sposoby ich stosowania
ZA202006066B (en) Anti-hla-g antibodies and use thereof
HUE048284T2 (hu) Anti-CD40 antitestek és alkalmazásuk
IL271260A (en) Multi-specific antibodies and methods of making and using thereof
HUE058957T2 (hu) Új T-sejt receptorok és velük végzett immunterápia
IL263627A (en) Chimeric antigen receptors (cars) specific for muc1 and methods for their use
PL3226897T3 (pl) Przeciwciała do celowania w antygen dojrzewania limfocytów b i sposoby ich zastosowania
EP3904382A4 (en) ANTI-IL-23P19 ANTIBODIES AND USES THEREOF
PT3148579T (pt) Anticorpos anti-gitr e métodos da sua utilização
IL283644A (en) Compositions and methods for immunotherapy
HUE046749T2 (hu) Antigénreceptorok és azok felhasználása
IL283875A (en) Anti-il-27 antibodies and uses thereof
IL281297A (en) Anti-npr1 antibodies and uses thereof
EP3157564C0 (en) ANTIBODY ANTAGONISTS OF ALPHA AND OMEGA INTERFERONS
IL282707A (en) Anti-tim-3 antibodies and their use
EP3700045A4 (en) CHARGING DEVICE AND CHARGING SYSTEM